Fulcrum Therapeutics Inc (NASDAQ:FULC) has a beta value of 2.10 and has seen 1.13 million shares traded in the last trading session. The company, currently valued at $244.88M, closed the last trade at $4.54 per share which meant it gained $0.12 on the day or 2.71% during that session. The FULC stock price is -201.76% off its 52-week high price of $13.70 and 37.0% above the 52-week low of $2.86. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.85 million shares traded. The 3-month trading volume is 1.02 million shares.

The consensus among analysts is that Fulcrum Therapeutics Inc (FULC) is Buy stock at the moment, with a recommendation rating of 2.62. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 4 out of 13 have rated it as a Hold, with 9 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.29.

Fulcrum Therapeutics Inc (NASDAQ:FULC) trade information

Sporting 2.71% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the FULC stock price touched $4.54 or saw a rise of 2.16%. Year-to-date, Fulcrum Therapeutics Inc shares have moved -32.74%, while the 5-day performance has seen it change 12.10%. Over the past 30 days, the shares of Fulcrum Therapeutics Inc (NASDAQ:FULC) have changed 51.08%. Short interest in the company has seen 4.97 million shares shorted with days to cover at 7.67.

Wall Street analysts have a consensus price target for the stock at $3.5, which means that the shares’ value could drop -29.71% from current levels. The projected low price target is $2.0 while the price target rests at a high of $4.0. In that case, then, we find that the current price level is 11.89% off the targeted high while a plunge would see the stock lose 55.95% from current levels.

Fulcrum Therapeutics Inc (FULC) estimates and forecasts

Figures show that Fulcrum Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -30.05% over the past 6 months, with this year growth rate of 89.94%, compared to 17.20% for the industry. Revenue growth from the last financial year stood is estimated to be 2,766.48%.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 1.09% over the past 5 years. Earnings growth for 2024 is a modest 90.48% while over the next 5 years, the company’s earnings are expected to increase by 16.40%.

FULC Dividends

Fulcrum Therapeutics Inc is expected to release its next earnings report in January this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Fulcrum Therapeutics Inc (NASDAQ:FULC)’s Major holders

Insiders own 1.62% of the company shares, while shares held by institutions stand at 89.70% with a share float percentage of 91.17%. Investors are also buoyed by the number of investors in a company, with Fulcrum Therapeutics Inc having a total of 165.0 institutions that hold shares in the company. The top two institutional holders are RA CAPITAL MANAGEMENT, L.P. with over 11.61 million shares worth more than $71.98 million. As of 2024-06-30, RA CAPITAL MANAGEMENT, L.P. held 18.7302% of shares outstanding.

The other major institutional holder is RTW INVESTMENTS, LP, with the holding of over 5.85 million shares as of 2024-06-30. The firm’s total holdings are worth over $36.24 million and represent 9.4314% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . As of Sep 30, 2024 , the former fund manager holds about 3.43% shares in the company for having 1.85 shares of worth $8.41 million while later fund manager owns 1.64 shares of worth $7.46 million as of Sep 30, 2024 , which makes it owner of about 3.05% of company’s outstanding stock.